Knight Therapeutics Q4 2023 Financial Performance Overview
Thursday, 21 March 2024, 11:38
Knight Therapeutics Q4 2023 Results Overview
Knight Therapeutics recently disclosed its financial performance for the fourth quarter of 2023, highlighting a GAAP EPS of -C$0.23 and revenue of C$74.2M, showing a 9.1% year-over-year decline. This update signals potential challenges for the company to address moving forward.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.